Improving melanoma treatment with a new type of mRNA shot
Multivalent Small Circular mRNA Vaccines for Melanoma Combination Immunotherapy
['FUNDING_R01'] · UNIVERSITY OF MICHIGAN AT ANN ARBOR · NIH-11140510
This research is creating a new kind of mRNA shot to make current melanoma treatments work better for more patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MICHIGAN AT ANN ARBOR (nih funded) |
| Locations | 1 site (ANN ARBOR, UNITED STATES) |
| Trial ID | NIH-11140510 on ClinicalTrials.gov |
What this research studies
Melanoma is a serious skin cancer, and while some immune therapies help, many patients don't get better. This project is developing a new type of mRNA shot, called small circular mRNA (circRNA), to help the body's immune system fight melanoma more effectively. Unlike traditional mRNA shots, these circRNA shots are designed to be more stable and last longer, potentially leading to a stronger and more lasting immune response against cancer cells. The goal is to combine these new shots with existing immune checkpoint blockade therapies to improve outcomes for patients.
Who could benefit from this research
Good fit: This research is ultimately aimed at patients with melanoma, especially those who do not respond well to current immune checkpoint blockade therapies.
Not a fit: Patients with other types of cancer or those who respond well to existing melanoma treatments may not directly benefit from this specific approach.
Why it matters
Potential benefit: If successful, this approach could make current immune therapies more effective for melanoma patients, leading to better treatment responses and potentially longer-lasting protection against the cancer.
How similar studies have performed: While conventional mRNA vaccines show promise for cancer, this specific approach using small circular mRNA is a novel strategy to overcome limitations of current mRNA technologies.
Where this research is happening
ANN ARBOR, UNITED STATES
- UNIVERSITY OF MICHIGAN AT ANN ARBOR — ANN ARBOR, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZHU, GUIZHI — UNIVERSITY OF MICHIGAN AT ANN ARBOR
- Study coordinator: ZHU, GUIZHI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.